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ARTICLE
Higher mortality rate is associated with 
advanced age and periodic lateralized 
epileptiform discharges in patients with 
refractory status epilepticus
Alta taxa de mortalidade está associada com idade avançada e descargas periódicas 
lateralizadas em pacientes com estado de mal epiléptico refratário
Paulo Breno Noronha Liberalesso, Eliana Garzon, Elza M.T. Yacubian, Américo C. Sakamoto
Status epilepticus (SE) is considered the main emergen-
cy in clinical neurology, requiring immediate diagnosis and 
treatment. Recent data suggest an incidence from 100,000 to 
200,000 cases, per year1.
The SE definitions proposed by the Committee of 
Classification and Terminology of the International League 
Against Epilepsy (ILAE – 1964 and 1981)2,3 do not consider 
the event duration factor. Therefore, different investigators 
have used different definitions, impairing the uniformity 
of the concept. Many authors consider SE a single epileptic 
seizure or two or more recurrent epileptic seizures without 
full recovery of consciousness, lasting 30 minutes or more4. 
This definition has been widely used over the last 20 years, 
although several authors have suggested that such con-
cept should include epileptic seizure lasting more than five 
or ten minutes5,6. However, the increase in mortality and in 
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ABSTRACT
Objective: To evaluate clinical data, electroencephalogram, etiology, classification, treatment, morbidity, and mortality in acute refractory 
status epilepticus. Methods: Fifteen patients, mean age of 41.3 years-old, six males, with refractory status epilepticus, were retrospectively 
studied. All of them were followed by serial electroencephalogram or continuous electroencephalographic monitoring. Results: The most 
common comorbidity was hypertension. Seven (46.7%) patients were diagnosed with previous symptomatic focal epilepsy. More than one 
etiology was identified in 40.0% of the cases. Status epilepticus partial complex was the most common (n=14, 93.3%), and discrete seizures 
were the most observed initial ictal pattern. Continuous intravenous midazolam was used in nine (60.0%) patients and continuous thiopental 
in three (20.0%). Nine (60.0%) participants died, one (6.6%) had neurological sequelae, and five (33.3%) presented no neurological sequelae. 
Conclusions: Higher mortality rate was associated with advanced age and periodic lateralized epileptiform discharges. Midazolam proved to 
be a safe drug. The refractory status epilepticus is related to high mortality.
Key words: status epilepticus, treatment, prognosis, age.
RESUMO
Objetivo: Avaliar os dados clínicos, o eletroencefalograma, a etiologia, a classificação, o tratamento, a morbidade e a mortalidade do estado 
de mal epiléptico. Métodos: Quinze pacientes, idade média de 41,3 anos, seis masculinos, foram avaliados retrospectivamente. Todos eles 
foram acompanhados por eletroencefalogramas seriados ou monitoração eletrencefalográfica contínua. Resultados: A comorbidade mais 
comum foi hipertensão arterial. Sete (46,7%) pacientes tinham epilepsia focal sintomática prévia. Mais de uma etiologia foi identificada em 
40,0% dos casos. O estado de mal epiléptico parcial complexo foi o mais frequente (n=14; 93,3%) e discrete seizures foram os padrões ictal 
inicial mais observados. Midazolam contínuo foi usado em nove (60,0%) pacientes e tiopental contínuo em três (20,0%). Nove (60,0%) partici-
pantes morreram, um (6,6%) teve sequelas neurológicas e cinco (33,3%) não apresentaram sequelas. Conclusões: Alta taxa de mortalidade 
foi associada com idade avançada e com a presença de descargas periódicas epileptiformes lateralizadas. Midazolam provou ser uma droga 
segura. Estado de mal epiléptico refratário está associado à alta mortalidade.
Palavras-Chave: estado de mal epiléptico, tratamento, prognóstico, idade.
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a definitive neurological lesion related to epileptic seizures 
with more than 30 minutes appears to justify the mainte-
nance of the current definition.
Epidemiological data regarding morbidity and mortal-
ity vary considerably and are closely related to patient’s 
age, etiology and duration of the seizures, early diagno-
sis, and therapeutic conduct adopted7,8. Studies on animal 
models have suggested that continuous and prolonged 
epileptiform activity per se may be related to irreversible 
neuronal damage9.
The most serious form of SE is denoted refractory SE 
(RSE), which is understood as SE that cannot be clinically 
and/or electrographically controlled with first and second 
line antiepileptic drugs (AED)10. Other authors consider SE to 
be refractory after failure of treatment with a third line AED11. 
Some of them reserve the term RSE for epileptic seizure, with 
more than one hour12,13, while others reserve the term for sei-
zures lasting more than two hours14. 
Clinical practice demonstrates that a considerable pro-
portion of patients with SE develop refractoriness to clinical 
treatment, although few studies are available with specific 
emphasis on the epidemiological aspects of RSE.
In the present study, we analyzed patients with RSE diag-
nosis in order to identify the etiology of the condition, to eval-
uate its clinical and electrographic evolution, the treatment, 
the complications during the acute phase, and the possible 
risk factors that contributed to mortality.
METHODS
All patients with RSE diagnosis admitted between January 
2001 and September 2004 were retrospectively identified. All 
medical records were reviewed by the same investigator, who 
also filled out all previously elaborated protocols. All partici-
pants were submitted to continuous electroencephalograph-
ic monitoring or to serial electroencephalographies (EEGs) 
lasting at least 20 minutes by using 21-channel digital equip-
ment (Nihon Koden® and NEUROTEC®), with the electrodes 
positioned according to the 10-20 International System. We 
evaluated demographic data; medical history, etiology and 
clinical classification of SE; electrographic patterns; use of 
first, second, and third line AED; treatment during RSE; and 
short-term prognosis.
For SE classification, we used the classification of epi-
leptic seizures and SE of Gastaut4: generalized convulsive SE 
(tonic-clonic, tonic, clonic, myoclonic); simple partial convul-
sive SE; nonconvulsive generalized SE; complex partial non-
convulsive SE; and simple partial nonconvulsive SE.
The following definitions were adopted:
•	 SE:	 a	 single	 epileptic	 seizure	 or	 two	 or	more	 recurrent	
ones without recovery of consciousness and lasting 30 
minutes or more.
•	 RSE:	SE	for	which	no	clinical	and/or	electrographic	con-
trol of the epileptic phenomenon was obtained after in-
travenous administration of appropriate doses of first 
and second line AED, such as benzodiazepines, phenyt-
oin, and phenobarbital.
•	 Ictal	 patterns:	 five	distinct	 patterns	were	 considered	—
discrete seizures (DS) merging seizures (MS), continuous 
ictal discharge (CID), CID with flat periods (CID-F), and 
periodic lateralized epileptic discharges (PLEDs).
•	 Control	 of	 SE:	 control	 was	 defined	 as	 the	 last	 clinical	
and/or electrographic seizure after which the patient 
did not suffer recurrence of an epileptic seizure for at 
least 48 hours.
•	 Failure	 of	 RSE	 treatment:	 permanence	 or	 recurrence	
within less than 48 hours after clinical and electrographic 
controls and the maximum tolerated dose of continuous-
ly infused midazolam, thiopental, or propofol.
•	 Minimum	tolerated	dose:	continuously	 infused	dose	of	
midazolam, thiopental or propofol related to the onset 
of severe side effects, which prevented the maintenance of 
the drug.
•	 Short-term	prognosis:	neurological	status	evaluated	dur-
ing the first two weeks after RSE control.
The study was approved by the Hospital Ethics and 
Human Research Committee (1312/02).
RESULTS
We clinically and electrographically evaluated 15 pa-
tients with a RSE diagnosis, six (40.0%) of them males, 
ranging in age from 1 to 84 years-old (mean: 41.3 years-old; 
median: 50 years-old), six by continuous electroencephalo-
graphic monitoring, and nine by serial EEGs (43 serial re-
cordings). Fourteen patients presented comorbidities, the 
most prevalent being systemic arterial hypertension (n=6; 
40.0%), chronic congestive heart failure (n=3; 20.0%), diabe-
tes mellitus (n=3; 20.0%), chronic renal failure (n=2; 13.3%), 
and ischemic cerebrovascular accident (n=2; 13.3%). Seven 
patients (46.7%) had a previous diagnosis of symptomatic 
focal epilepsy (Table 1).
It was possible to identify the etiology of RSE in all cas-
es, with more than one etiology being detected in six (40.0%) 
patients. Fourteen (93.3%) cases were classified as complex 
partial SE and one (6.7%) as myoclonic SE. The most frequent 
initial ictal pattern was DS (n=6; 40%), with more than one 
ictal pattern being recorded in eight (53.3%) cases during the 
course of RSE. PLEDs occurred in three (20.0%) cases as the 
initial ictal pattern and during the course of RSE in one (6.7%) 
of them (Table 1).
Diazepam was used as the most frequent first line 
AED (n=6; 40.0%), phenytoin as the second (n=8; 53.3%), 
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Table 1. Demographic data, base diseases, epilepsy, classification of status epilepticus, and ictal patterns.
Patient Sex Age Base diseases Epilepsy Etiology Classification Ictal patterns
1 F 53 SAH, neurocysticercosis, chronic gastritis Yes
Neurocysticercosis, intracranial 
hypertension Complex partial
PLEDs, CID,  
CID-F, DS
2 F 50 Glioblastoma Yes Sepsis Complex partial DS, MS
3 M 59 SAHChronic renal failure No Metabolic disorder, sepsis Complex partial CID
4 F 84 SAH, Parkinson’s disease, chronic heart failure No Traumatic brain injury Complex partial PLEDs, MS
5 M 81 SAH, DM, rectal neoplasia, chronic heart failure No Cardiorespiratory arrest Myoclonic CID-F
6 M 26 Aids No Structural brain lesion, meningitis Complex partial PLEDs
7 M 21 Live cirrhosis; chronic renal failure No Metabolic disorder, sepsis Complex partial MS
8 F 69 SAH, CVAI Yes Sepsis Complex partial CID-F, PLEDs
9 F 3 Mucopolysaccharidosis Yes Cardiorespiratory arrest Complex partial MS, CID, CID-F
10 F 84 SAH, DMChronic heart failure No CVAI Complex partial CID
11 M 50 DM, CVAI Yes Metabolic disorder, sepsis Complex partial DS
12 F 7 Rhinopharynx rhabdomyosarcoma No Brain metastasis Complex partial DS
13 F 1 --- Yes Pneumonia, respiratory insufficiency Complex partial DS, MS, CID
14 F 23 --- No Postvaccinal encephalitis Complex partial DS, MS
15 M 9 Postencephalitis sequel Yes Decompensation of symptomatic focal epilepsy Complex partial DS, MS
F: female; M: male; SAH: systemic arterial hypertension; DM: diabetes mellitus: Aids: acquired immunodeficiency syndrome; CVAI: ischemic cerebrovascular 
accident; PLEDs: periodic lateralized epileptiform discharges; CID: continuous ictal discharges; CID-F: continuous ictal discharges with flat periods; MS: merging 
seizures; DS: discrete seizures.
and phenobarbital as the third (n=7; 46.7%). After RSE 
diagnosis, continuous intravenous infusion of midazol-
am was used for nine (60.0%) patients, followed by con-
tinuous thiopental in three cases. In six (40.0%) patients, 
after the detection of RSE, the option was treatment by 
polytherapy without infusion of midazolam and/or thio-
pental (Table 2).
In the group of patients treated with continuous midazol-
am (n=7), the mean attack dose was 10.5 mg, and the mean 
maximum dose reached was 0.42 mg/kg/h, with a mean use 
time of 4.2 days. During continuous midazolam infusion, an 
adverse effect of the drug was observed in three (20.0%) pa-
tients (arterial hypotension), with the administration of do-
pamine being necessary in two cases (Table 2).
Three patients were treated with continuous thio-
pental infusion, with a mean maximum dose reached of 
3.9 mg/kg/h and a mean time of use of 3.5 days. The three 
patients presented arterial hypotension during infusion of 
the drug, with the administration of dopamine being nec-
essary in two cases and discontinuation of the drug being 
required in only one.
Regarding the short-term course, nine (60.0%) patients 
died, five (33.3%) had no neurological sequels, and one 
(6.6%) had neurological sequels. In six (40.0%) patients, it 
was possible to obtain control of RSE within a mean time 
of 33.6 hours.
DISCUSSION
RSE physiopathology has peculiarities related to its du-
ration and severity, with emphasis on hypoglycemia second-
ary to excessive insulin release, faulty self-regulation of cere-
bral blood flow, excitotoxic neuronal damage, brain edema, 
increased body temperature related to muscle activity, and 
during a later phase multiple organ and system dysfunction 
followed by cardiovascular failure11,15. RSE has peculiar char-
acteristics compared to SE, with a higher risk of complica-
tions and morbidity and mortality.
Age and sex
Although practically half the cases of SE affect children 
and adolescents, several studies have demonstrated that in-
dividuals above the age of 60 years represent a population at 
risk15,16. In general, SE seems to present a bimodal age distri-
bution, with a first incidence peak among children young-
er than 12 months and another among elderly patients2. In 
the present series, most of the patients were adults (73.3%). 
Approximately two thirds of the patients were older than 
50 years-old and one third was older than 80, suggesting that 
increasing age is accompanied by an increasing risk of refrac-
toriness in cases of SE.
Regarding distribution by gender, literature data are con-
flicting, some studies demonstrate a predominance of SE 
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among males16, while others show predominance among fe-
males17. In the present study we observed a predominance 
among females (n=9; 60.0%)
Comorbidities and etiology
Approximately one third of SE cases are deemed idio-
pathic, occurring in neurologically healthy individuals and 
representing the first manifestation of an epileptic picture18,19.
Age and presence of previous unprovoked epileptic sei-
zures are important aspects for the evaluation of SE etiol-
ogy. Among children and small infants, febrile/infectious 
situations, anoxic lesions, traumatic brain injury, meningo-
encephalitis and chronic nonprogressive encephalopathy 
are responsible for a considerable portion of SE cases19,20; 
whereas among adults and elderly individuals, cerebro-
vascular disorders metabolic disorders and infection of 
the central nervous system are the most frequent16,17,21,22. 
Among previously epileptic patients, changes in the treat-
ment scheme or irregular use of AED is the factor triggering 
SE in most situations22. In a large study involving more than 
200 patients, Barry and Hauser23 suggested that a meticu-
lous investigation of SE etiology should be performed even 
in previously epileptic patients, since half of these patients 
have a base disease or an acute brain injury as the factor 
triggering the current SE.
The etiology was classified as acute symptomatic in 
14 (93.3%) of our patients. SE was due to decompensation 
of previous symptomatic focal epilepsy in only one of our 
cases. Sepsis and metabolic disorders were conspicuous 
for their high frequency. In contrast to the literature, the 
etiology related to cerebral ischemia was infrequent in our 
series, with only one case secondary to an ischemic cere-
brovascular accident and two secondary to cardiorespira-
tory arrest being observed.
Probably due to the predominance of elderly patients in 
our study, comorbidities were present in most cases (n=13; 
86.7%), with emphasis on systemic arterial hypertension, dia-
betes mellitus, and chronic congestive heart failure. The pres-
ence of comorbidities/base diseases among elderly patients 
may impair the etiologic identification of SE.
A previous history of symptomatic focal epilepsy was 
observed in practically half of our patients (n=7; 46.7%), al-
though decompensation of previous refractory epilepsy was 
implicated as the etiology in only one case.
Classification of refractory status epilepticus
According to Gastaut4, SE can be classified as gener-
alized convulsive (tonic-clonic, tonic, clonic, myoclonic); 
simple partial convulsive (somatomotor, postural motor, 
continuous partial epilepsy); generalized nonconvulsive 
(typical and atypical absence); simple partial nonconvul-
sive (somatosensory, sensory, autonomic, psychic or affec-
tive, motor inhibitory), and complex partial nonconvulsive. 
Except for one of our patients diagnosed as having myo-
clonic RSE, all others presented complex partial RSE. These 
data agree with the current literature, which indicates that 
complex partial SE is the most frequent condition in criti-
cally ill adult and elderly patients8.
Several studies have demonstrated that clinical evalua-
tion may be insufficient for the diagnosis and classification 
Table 2. Patients treated with continuous midazolam and short-term evolution of refractory status epilepticus.
Patient Age Attack dose  
(MDZ)
Maximum dose
(MDZ)
Time of use
(MDZ)
Adverse effects
(MDZ)
Treatment of
RSE
Ictal 
patterns
RSE 
outcome
1 53 15 mg 0.45 5 days No MDZ, THP PLEDs, CID, CID-F, DS Death
2 50 15 mg 0.40 4 days No MDZ DS, MS Death
3 59 10 mg 0.25 6 days No MDZ CID Death
4 84 15 mg 0.35 6 days No MDZ PLEDs, MS Death
5 81 10 mg 0.25 3 days Systemic arterial hypotension MDZ CID-F Death
6 26 10 mg 0.40 3 days No MDZ, THP PLEDs Death
7 21 – – – – PB, PHT MS Control
8 69 – – – – PB, PHT CID-F, PLEDs Control
9 3 4.5 mg 0.65 6 days No MDZ MS, CID, CID-F Control
10 84 – – – – PB, PHT CID Death
11 50 – – – – PB, PHT DS Death
12 7 – – – – PB, PHT DS Control
13 1 – – – – PB, PHT, TPM DS, MS, CID Control
14 23 10 mg 0.8 2 days Systemic arterial hypotension
MDZ, THP
Propofol DS, MS Death
15 9 5,0 mg 0.2 3 days Systemic arterial hypotension
VPA, PB, PHT, 
MDZ DS, MS Control
MDZ: midazolam; Maximum dose in mg/kg/day; THP: thiopental; PB: phenobarbital; PHT: phenytoin; TPM: topiramate; VPA: sodium valproate; RSE: refractory 
status epilepticus; PLEDs: periodic lateralized epileptiform discharges; CID: continuous ictal discharges; CID-F: continuous ictal discharges with flat periods; 
MS: merging seizures; DS: discrete seizures.
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of SE, with serial or continuous electroencephalographic re-
cordings being required. According to DeLorenzo24, about 8% 
of comatose patients with no motor manifestation sugges-
tive of epileptic seizures are in nonconvulsive SE, and this di-
agnosis can be confirmed exclusively by the EEG. The perma-
nence of continuous epileptiform activity over a prolonged 
period is positively related to increased mortality and neu-
rological morbidity, and diagnosis and treatment should be 
established as early as possible25. In our series, two patients 
were unconscious and did not show any motor manifesta-
tion that might suggest the presence of epileptic seizures, re-
vealing the importance of the EEG for the investigation of pa-
tients in a comatose state.
Ictal patterns
Treiman et al.26 suggested the existence of five ictal pat-
terns that represent the natural history of the electrograph-
ic course of SE: DS with interictal slowing (this ictal pattern 
was observed as the initial ictal pattern in six cases and dur-
ing the course of RSE in one case); MS (this ictal pattern was 
observed in two cases as the initial ictal pattern and in five 
cases during the course of RSE); continuous ictal discharges 
(this ictal pattern was observed in the initial recording in two 
of our cases and during the course of SE in three other cas-
es); continuous ictal discharges with flat periods (this pattern 
was initially observed in two cases and during the course of 
SE in two other patients); and PLEDs (this pattern was ob-
served in the initial recording in three patients and during 
the course of RSE in only one case).
PLEDs represent an electrographic finding of particularly 
difficult interpretation, with many investigators considering 
them an unequivocal ictal pattern27, although they may be 
observed in situations not related to SE.
In contrast to the results reported by Treiman et al.26 re-
garding patients with generalized convulsive SE, our data did 
not confirm the presence of a stereotyped sequence of ictal 
patterns during the course of complex partial SE.
Treatment
The objective of treating patients with SE is clinical and 
electrographic controls within the shortest possible time, 
since there is evidence suggesting that a longer duration of SE 
is accompanied by an increased refractoriness to treatment.
Although SE diagnosis is based on at least 30 minutes of 
continuous ictal activity, this theoretical definition has no 
implications regarding the decision about the beginning of 
clinical treatment. Although there are variations in proto-
cols, most authors consider benzodiazepines, phenytoin, and 
phenobarbital the AED of choice for the initial management 
of these patients. In a study in which 111 SE episodes were 
evaluated clinically and electrographically in 102 patients, 
SE could not be controlled with first or second line AED in 
11.7% of cases, which corresponded to RSE. Benzodiazepines 
are potent AED that should be used only in the presence of 
epileptic seizures, always accompanied by another AED 
of longer-lasting action such as the phenytoin. Intravenous 
formulations of diazepam and lorazepam (the latter not 
available in Brazil) are the first line drugs most commonly 
used, because of their rapid initiation of action due to their 
high liposolubility28,29.
Phenobarbital has been used in many cases as a second 
line drug in the treatment of SE, especially in newborn and 
young infants. Shaner et al.29 compared the efficacy of phe-
nobarbital and diazepam in combination with phenytoin for 
the initial treatment of SE, but they observed no significant 
differences between treatments. 
Patients with nonconvulsive SE, particularly those with 
a history of epilepsy, should not be treated in an aggressive 
manner such as by induction of barbituric coma, which in-
creases the risk of neurological morbidity and mortality, off-
setting the benefits of early control of SE.
In the present study, the first line AED most frequently 
used for the treatment of SE was diazepam, the second 
line drug was phenytoin and the third one was phenobar-
bital. Once RSE was observed, continuous infusion of mid-
azolam was the therapeutic conduct in most cases, with 
systemic arterial hypotension being detected as a side ef-
fect in three patients and easily controlled with dopamine. 
The three patients treated with thiopental developed se-
vere systemic arterial hypotension, which required dis-
continuation of the drug in one case and treatment with 
dopamine in the other two.
Short-term prognosis
Several series have demonstrated that the prognosis of 
patients with SE is closely related to etiology and that both 
mortality and risk of neurological sequels are more frequent 
among adults/elderly subjects than among children30.
The morbidity-mortality rate varies considerably in dif-
ferent studies depending on factors such as patient age, 
presence of base diseases and clinical complications, classi-
fication of SE, and the therapeutic conduct adopted. Maytal 
et al.30, studying aspects related to prognosis in 193 children 
and adolescents who had presented SE, observed a 3.6% 
mortality rate during the first three months and a 9.1% of 
neurological sequels. These values were significantly low-
er than those detected by other investigators in a series of 
adults/elderly subjects with SE, in which mortality ranged 
from 9.3 to 88.0%16,17.
Other factors in addition to advanced age seem to be as-
sociated with poorer prognosis, such as the presence of ce-
rebral anoxia, low voltage cerebral electrical activity and 
PLEDs in the EEG, lack of response to first and second line 
AED (RSE), lasting of more than one hour, and combination 
of more than one etiological factor. Mortality, neurological 
morbidity, and risk of later epilepsy are significantly higher 
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in RSE than in nonrefractory SE22. On the other hand, cases 
related to discontinuation or alteration of AED among previ-
ously epileptic patients and those related to alcoholism have 
lower morbidity-mortality. Other aspects such as sex and 
race do not seem to affect the prognosis of SE22.
Regarding the short-term prognosis, the present data 
agree with those reported in the literature, with more than 
half of our patients (n=9; 60%) dying, and approximately one 
quarter showing no additional neurological sequels during 
the first two weeks after controlling RSE.
In conclusion, in the present series we observed a pre-
dominance of RSE in adults/elderly individuals, with two 
thirds of our patients being over the age of 50. All patients 
older than more 80 years-old and more than half of the ones 
older than 50 years-old died, confirming the high mortality 
rate occurring in elderly individuals.
All patients who presented PLEDs at some time during 
the course of RSE died, confirming previous literature reports 
that associate this ictal pattern with high mortality rate. The 
presence of previous symptomatic focal epilepsy did not af-
fect the prognosis of RSE.
Treatment of RSE with continuous midazolam infusion 
proved to be safe, with side effects being observed and easily 
controlled in three cases. In contrast, the administration of 
thiopental was accompanied by severe hypotension, requir-
ing discontinuation of the drug in one patient.
Despite adequate treatment, RSE is related to a high rate 
of neurological mortality and morbidity.
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